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Kidney stones and renal failure are more common in patients with CF compared to
general population. Hyperoxaluria caused by fat malabsorption and the lack of in-
testinal oxalate degrading bacteria Oxalobacter formigenes is known in CF patients.
Hyperoxaluria-induced crystal formation is associated with kidney stones and renal
failure. However data concerning detection of crystals in CF patients are lacking
in the literature. We conducted a prospective study in Pneumology Center, Foch
Hospital, during 8 months.
Forty cystic ﬁbrosis adult patients were enrolled to have a sample spot urine test
on the ﬁrst morning micturition. Median age was 29 years-old (range 20−55).
Sixteen patients were pulmonary transplanted. Thirty-eight (95%) and 24 (61%)
patients had exocrine and endocrine pancreas insufﬁciency, respectively. Three
patients had glomerulonephropathy (2 diabetic nephropathy and 1 amyloidosis).
The median plasmatic creatinine was 69mmol/l (range 39–400mmol/l). Factors
for crystals formation were researched. Thirty-ﬁve percent of patients (13/40) had
hypercalciuria (>3.5mmol/l), 60% (24/40) had hypershy;oxaluria (>0.3mmol/l) and
72% (28/40) had hypocitraturia (<1mmol/l). Crystalluria was present in 30 percent
of patients (12/40). All crystals were made of calcium and oxalate. All ﬁve patients
who had symptomatic kidney stones had positive crystalluria. Systematic screening
of urine crystals should be of beneﬁt in this population. Efﬁcient therapeutic
measures could be started easily to prevent kidney stone formation and crystal
nephropathy.
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Background: It has been shown that patients with cystic ﬁbrosis (CF) have impaired
fatty acid (FA) metabolism and decreased levels of DHA in plasma.
Hypothesis: FA levels may also be different in mild CF patients with and without
small airway disease (SAD).
Methods: In our study we examined 27 patients (6−55 years of age) with mild CF
(FEV1 >75%) and 15 control subjects (7−23 years of age). Patients were assigned
to two groups according to SAD deﬁned as MEF25 <50%: Group 1 without SAD
(n = 18) and Group 2 with SAD (n = 9). Induced sputum and blood status of FAs
(EPA, DHA, AA) were analyzed by tandem mass spectroscopy.
Results: As expected, trapped air (RV/TLC) was signiﬁcantly increased in patients
with SAD only (RV/TLC: control 84.75% vs. Group 1 109.3% vs. Group 2 158.50%,
p< 0.005) and sputum neutrophils were elevated compared to controls but not
signiﬁcantly different within patient groups (neutrophils: control 2%, Group 1 18%,
Group 2 55%, p< 0.01). Levels of AA and EPA were not altered, whereas DHA
was signiﬁcantly lower in CF (DHA: control 45.0mg/l vs. Group 1 32.7mg/l vs.
Group 2 30.0mg/l, p< 0.001), but DHA was not different between patient groups.
Conclusion: Our study showed that DHA plasma levels were signiﬁcantly reduced
and neutrophilic inﬂammation increased in mild CF. Inﬂammation and DHA
disturbance was not aggravated in patients with SAD most likely due to the small
patient sample studied.
246 Correlation of bone status with age and genotype in cystic
ﬁbrosis patients
S. Sciuca1, O. Turcu1. 1State Medical and Pharmaceutical University, Pediatrics,
Chisinau, Moldova
Aim: To assess the frequency of body mineral density (BMD) disorders in patients
with cystic ﬁbrosis (CF).
Material and Methods: The study included 17 patients with CF (8 boys) with the
mean age 13.34±1.32 years. The CF diagnosis was conﬁrmed by a positive sweat
test result and CFTR gene analysis. F508del mutation was revealed in 64.7% cases.
The age groups consisted of 7 children aged <12 years and 10 patients >12 years.
BMD in CF patients was measured using the DEXA scanner (Hologic Inc., USA).
Z-score was used for bone status evaluation, as standard deviation (DS) from the
mean BMD of an age- and gender-matched control population (Z-score >−1DS;
osteopenia − Z-score <−1DS and >−2.5DS; osteoporosis − Z-score <−2.5DS).
Results: DEXA examination identiﬁed normal values of BMD in 18.75% of
children, signs of osteopenia in 50.0% of patients and osteoporosis in 31.30% of
children. Z-scores in 81.3% of children were signiﬁcantly lower (−1.78±0.27 DS)
than age-normal values. In the group of children <12 years 14.28% of cases
presented with normal BMD, 57.14% with osteopenia and 29% with osteoporosis
and the mean value of Z-score −1.31±0.38 DS. In patients >12 years in 12.5%
cases the BMD was normal, 50% − osteopenia, 37.5% − osteoporosis and Z-score
was −2.30±0.29 DS, pointing severe BMD reduction or osteoporosis. The F508del
genotype was associated with a lower value of BMD (−2.16±0.28) in comparison
with non-F508del mutations (−0.94±0.54).
Conclusion: DEXA examination showed a progression of BMD disorders with
the age in children with CF. F508del mutation was conﬁrmed as a risk factor in
developing bone complications as reduced mineralization.
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Objectives: Vitamin D (VtD) remains of uncertain clinical signiﬁcance in CF.
VtD levels are typically low, even with normal pancreatic function. We explored
potential associations of VtD with major clinical variables.
Methods:We collected Annual Review (AR) data (2009) from our Adult CF Centre
of 605 patients. Serum 25-hydroxyvitamin D (25OHD) and various clinical param-
eters were explored for potential associations; data was analyzed as both categorical
and continuous variables (Stata v10).
Results: 373 patients with sufﬁcient data showed the following baseline character-
istics: 54% male (n = 200); 13% (n = 48) BMI <19 kg/m2, 68% (255) 19−25 kg/m2
and 19% (70) >25 kg/m2; 99% (370) Caucasian. VtD levels classiﬁed according
to CF Trust 2007 criteria were optimal (75 nmol/l) in 15% (n = 55), adequate
(50−74 nmol/l) in 40% (150), insufﬁcient (25−49 nmol/l) in 34% (125) and
deﬁcient (<25 nmol/l) in 12% (43). There was no signiﬁcant seasonal variation
of VtD levels. VtD levels were not signiﬁcantly associated with percentage of
predicted FEV1 or FVC, use of intravenous antibiotics, HbA1c, BMI, presence of
Pseudomonas or Aspergillus, and bone mineral density. Low VtD may be associated
with pancreatic insufﬁciency (PI) compared to pancreatic sufﬁciency (PS) with a
trend towards statistical signiﬁcance (PI mean VtD level 50.6±20.4 nmol/l, PS mean
57.0±27.9 nmol/l; p = 0.07).
Conclusions: VtD levels were low in 46% of our cohort with some association with
PI. Unlike previous reported data, we have not observed any signiﬁcant association
of VtD levels with the major CF clinical variables in our large cohort.
